Gui Bin She International Holding Group (GBS)

Gui Bin She International Holding Group will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About GBS

Founded in 2016, Shenzhen GBS Hotel Group is headquartered in Futian CBD, Shenzhen, featuring a compendious French style created by a renowned brand designing company. GBS is positioned as a French-style medium-and-high-end business hotel chain, providing customers with healthy, safe, comfortable, and environmentally friendly accommodations. By providing unique VIP services and first-class ambiance, we strive to create a affordable luxury travel experience for customers, and are committed to forging a national brand model. To date, GBS has dire... [Read more]

Industry Lodging
Founded 2016
Country CHINA
Stock Exchange NASDAQ
Ticker Symbol GBS
Full Company Profile

News

GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (IBSS) and Announces Key Executive Appointments

- Name change to more closely reflect firm's expanding portfolio of intelligent, efficient, convenient and practical noninvasive and drug testing technologies and products -

1 year ago - GlobeNewsWire

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) --  GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners a...

1 year ago - GlobeNewsWire

GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights

- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition -

1 year ago - GlobeNewsWire

GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

2 years ago - GlobeNewsWire

GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood

NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...

2 years ago - GlobeNewsWire

GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...

2 years ago - GlobeNewsWire

GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022

NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...

2 years ago - GlobeNewsWire

GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse

- Intelligent Fingerprinting Limited's commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipeline - Intelligent Fingerp...

2 years ago - GlobeNewsWire

GBS Inc. to Present at the H.C. Wainwright Global Investment Conference

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at ...

2 years ago - GlobeNewsWire

GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET

NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at ...

2 years ago - GlobeNewsWire

GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights

- Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval -

2 years ago - GlobeNewsWire

GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

2 years ago - GlobeNewsWire

GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center

The trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose

2 years ago - GlobeNewsWire

GBS Inc. to Participate in the Upcoming March Investor Conferences

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at poi...

2 years ago - GlobeNewsWire

GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government -

2 years ago - GlobeNewsWire

GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

2 years ago - GlobeNewsWire

GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences

NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at poin...

2 years ago - GlobeNewsWire

GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...

2 years ago - GlobeNewsWire

GBS Shares Are Rallying On Plans For COVID-19 Antibody Trials After Validation Study

GBS Inc (NASDAQ:GBS) will prepare for clinical trials of its rapid SARS-CoV-2 (COVID-19) Antibody test following the recent successful completion of a clinical validation study. As previously referenc...

2 years ago - Benzinga

GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...

2 years ago - GlobeNewsWire

GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test –

2 years ago - GlobeNewsWire

GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

2 years ago - GlobeNewsWire

GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...

2 years ago - GlobeNewsWire

FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick

SYDNEY, Oct. 19, 2021 /PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensee...

2 years ago - PRNewsWire

GBS Inc. Announces its Pre-Submission package is with the FDA

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...

2 years ago - GlobeNewsWire